encourages correct prescription drug use for a particular diagnosis, promotes the safe use of prescription drugs, and helps reduce drug costs.
|
|
- Alicia Goodwin
- 6 years ago
- Views:
Transcription
1 Prior Authorization Your health plan participates in a Prior Authorization (PA) program for specific prescription drugs. This means that Caremark must review certain information provided by your doctor to determine if benefits can be paid for that drug. The PA program: encourages correct prescription drug use for a particular diagnosis, promotes the safe use of prescription drugs, and helps reduce drug costs. How does the PA process work? The PA program includes a list of prescription drugs that require a review of information received from your doctor to determine if benefits can be paid for that drug. You only need to get the prescription, Caremark works with your doctor and pharmacy do the rest. 1. You get a prescription from your doctor for a drug listed below and give it to a retail pharmacy or mail service. 2. The pharmacy submits the prescription claim online to Caremark. 3. Caremark sends a reply message to the pharmacy explaining that authorization is necessary before benefits can be paid. The message also tells the pharmacy to contact Caremark to start the PA process. 4. The pharmacy begins the PA process. 5. Caremark works with your pharmacist and doctor to get the information needed for the review. 6. Your doctor provides the requested information to Caremark. 7. Caremark reviews the information and sends a letter to you and your doctor to let you know if benefits are approved or denied. If benefits are approved, your regular copays and deductibles will apply. If benefits are denied, you can appeal the denial. For questions regarding the PA program, please contact Caremark Customer Care tollfree at (888) TDD (telecommunications device for the deaf) users please call toll-free (800) The drugs listed below are part of the PA program for HealthSelect SM of Texas members. Caremark updates this list periodically, as it is subject to change if your plan changes. Non Specialty Medications Drug Category/Condition Specific Drugs that require a PA Notes Actinic Keratosis Solaraze Antifungal Jublia, Kerydin Clomid Clomid, Milophene, Serophene Compounded Medication Compounded Medication PA required if $300 or more
2 Neuropathic pain Osteoarthritis Pain Influenza prevention Narcolepsy Lidoderm Voltaren 1% Gel, Pennsaid Solution Relenza, Tamiflu Xyrem PA required if additional quantities are required past the quantity limit Pain Management Oxycontin, Stadol, PA required if additional quantities are required past the quantity limit Pain Management Cont Topical Pain Specialty Medications Abstal, Actiq, Fentora, Lazanda, Onsolis, Subsys, Fentanyl Oral EMLA, Lidocaine gel, Lidocaine Ontiment, Lidocaine Solution, Pliaglis, Synera Drug Category/Condition Specific Drugs that require a PA Retinal Disorders Allergic Asthma Bone Disorders Cryopyrin Associated Periodic Syndromes (CAPS) Neutropenia Coagulation Disorders Cystic Fibrosis Anemia Gastrointestinal Disorders Other Avastin, Macugen, Lucentis, Visudyne, Eylea Xolair, Nucala Strensiq Arcalyst, Kineret, Ilaris Leukine, Neupogen, Neulasta, Granix Ceprotin Pulmozyme, Tobi, Cayston, Kalydeco, Tobi-Podhaler, Bethkis, Orkambi, Kitabis Pak Aranesp, Procrit, Epogen, Omontys Gattex, Zorbtive, Cholbam, Ocaliva Growth Hormone and related disorders Genotropin, Increlex, Nutropin, Omnitrope, Humatrope, Norditropin, Nutropin AQ, Tev-Tropin, Saizen Hematopoietics Hemophilia and related bleeding disorders Hepatitis C HIV Mozobil, Neumega Stimate Infergen, Pegasys, Ribavirin (Copegus, Rebetol, Ribasphere), Intron A, PegIntron, Incivek, Victrelis, Olysio, Sovaldi, Harvnoi Fuzeon, Egrifta, Serostim
3 Hormonal Therapies Firmagon, Lupron, Leuprolide Acetate, Trelstar Dep/LA/Mix, Zoladex, Vantas, Lupron Depot, Eligard, Lupaneta, Aveed, Natpara Idiopathic Pulmonary Fibrosis Ofev, Esbriet Inflammatory Bowel Disease Humira, Remicade, Tysabri, Cimzia, Simponi, Entyvio Immune Therapies Carimune NF, Flebogamma, Gammagard, Gamunex, Octagam, Vivaglobin, Rho(D) immune globulin (RhoGAM, HyperRho, Rhophylac, Win Rho), Cytogam, GamaSTAN SD, Gammaplex, Hizentra, Privigen, Hepatitis B immune globulin (HepaGam B, HyperHep B S/D, Nabi-HB), Bivigam, Hyqvia Infertility Chorionic, ganirelex acetate, Gonal-F, Menopur, Repronex, Cetrotide, Follistim AQ, leuprolide acetate (Lupron), Ovidrel Iron Overload Exjade, Desferal, deferoxamine, Ferriprox, Jadenu Lipid Disorders Juxtapid, Kynamro, Repatha Lysosomal Storage Disorders Adagen, Cystagon, Orgadin, Zavesca, Cystaran, Procysbi, Cerdelga Multiple Sclerosis Avonex, Copaxone, Rebif, Extavia, Gilenya, Betaseron, Mitoxantrone, Ampyra, Tysabri, Aubagio, Tecfidera, Lemtrada, Plegridy
4 Oncology Osteoporosis Phenylketonuria (PKU) Pre-term Birth Afinitor, Avastin, Dacogen, Erbitux, Gleevec, Herceptin, Hycamtin Capsules, Intron A, Iressa, Ixempra, Nexavar, Mitoxantrone, Proleukin, Revlimid, Rituxan, Sprycel, Sutent, Tarceva, Tasigna, Temodar, Thalomid, Torisel, Treanda, Tykerb, Vectibix, Velcade, Vidaza, Xeloda, Zolinza, Zometa, Folotyn, Votrient, Arzerra, Istodax, Oforta, Thyrogen, Jevtana, Fusilev, Valstar, Xgeva, Halaven, Yervoy, Sylatron, Vandetanib, Zytiga, Adcetris, Xalkori, Zelboraf, Jakafi, Erwinaze, Elspar, Oncaspar, Inlyta, Erivedge, Voraxaze, Targretin, Perjeta, Kyprolis, Zaltrap, Xtandi, Bosulif, Stivarga, Synribo, Cometriq, Iclusig, Pomalyst, Kadcyla, Mekinist, Tafinlar, Gilotrif, Valchlor Gel, Gazyva, Imbruvica, Keytruda, Blincyto, Opdivo, Lynparza, Ibrance, Unituxin, Iressa, Darzalex, Empliciti, Tagrisso, Venclexta, Tecentriq, Lenvima, Lonsurf, Imlygic, Ninlaro Forteo, Prolia, Reclast (zoledronic acid) Kuvan Makena Psoriasis Amevive, Humira, Stelara, Enbrel, Remicade, Otrexup, Otezla, Rasuvo Pulmonary Arterial Hypertension Renal RSV (infant respiratory virus) Rheumatoid Arthritis Adcirca, epoprostenol (Flolan, Veletri), Letairis, Remodulin, Revatio (sildenafil), Ventavis, Tyvaso, Tracleer, Adempas, Opsumit, Orenitram, Uptravi Sensipar, Synagis Cimzia, Enbrel, Humira, Kineret, Orencia, Remicade, Actemra, Simponi, Simponi Aria, Rituxan, Xeljanz, Otezla, Otrezup, Rasuvo Seizure Disorders Acthar, Sabril Sleep Disorders Hetlioz Systemic Lupus Erythematosus (SLE) Benlysta Acromegaly Alcohol & Opioid Dependency octreotide acetate (Sando-statin), Sandostatin LAR, Somavert, Somatuline Depot, Signifor Vivitrol
5 Botulinum Toxins Botox, Myobloc, Dysport, Xeomin Cardiac Disorder Tikosyn Dupuytren s contracture Xiaflex Electrolyte Disorders Samsca Idiopathic Thrombocytopenic Purpura (ITP) Nplate, Promacta Lipodystrophy Myalept Infectious Disease Actimmune, Alferon -N Movement Disorders Apokyn, Xenazine, Nuplazid Pain Management Prialt Gout Therapies Urea Cycle Disorders Paroxysmal Nocturnal Hemoglobin-uria (PNH) Cushing s Syndrome Central Precocious Puberty (CPP) Krystexxa Carbiglu, Ravicti, Buphenyl Soliris Korlym, Signifor Leuprolide Acetate (CPP)(Lupron Depot-Ped), Leuprolide Acetate (CPP)(3month)(Leupron Depot-Ped), Supprelin LA
April 2015 NALC Specialty Pharmacy Drug List Providing one of the broadest offerings of specialty pharmaceuticals in the industry
NALC Specialty Pharmacy Drug List Providing one of the broadest offerings of specialty pharmaceuticals in the industry The NALC Specialty Pharmacy Drug List is a guide of medications available through
More informationJanuary 2018 Updated 12/01/2017 Advanced Control Specialty Formulary
January 2018 Updated 12/01/2017 Advanced Control Specialty Formulary The CVS Caremark Advanced Control Specialty Formulary is a guide within select therapeutic categories for clients, plan members and
More informationHow to search for a Pharmacy or Drug using the Express Scripts website
How to search for a Pharmacy or Drug using the Express Scripts website You are able to look for a participating pharmacy or a particular drug using the following website: https://host1.medcohealth.com/consumer/site/openenrollment?accesscode=natplsnaprf14&pagename=oeinfo
More informationPrior Authorization and Voluntary Preservice Determination Requests for Certain Pharmacy Drugs
October 2016 Prior Authorization and Voluntary Preservice Determination Requests for Certain Pharmacy Drugs Important Changes We want to let you know that on November 14, 2016, we will change prior authorization
More informationSpecialty drug coverage
Specialty drug coverage For members with the Aetna Value plan, Value Plus plan and Premier plan 2017 Aetna Specialty Drug List 54.03.439.1 C (7/17) aetna.com You may get your first fill of these drugs
More informationSpecialty drug coverage
Specialty drug coverage For members with the Aetna Premier Plus plan 2018 Aetna Specialty Drug List 05.03.429.1 E (9/17) aetna.com You may fill these drugs at an in-network specialty pharmacy, like Aetna
More informationSpecialty drug coverage
Specialty drug coverage For members with the Aetna Value plan, Value Plus plan and Premier plan 2018 Aetna Specialty Drug List 05.03.439.1 H (9/17) aetna.com You may get your first fill of these drugs
More informationMEDICATION AUTHORIZATION WORKFLOW FOR DRUGS THAT REQUIRE PRIOR-AUTHORIZATION (03/23/18) BASED ON LOCATION WHERE DRUG WILL BE ADMINISTERED
J9264 Injection, paclitaxel protein-bound particles, 1 mg ABRAXANE J3262 Injection, tocilizumab, 1 mg ACTEMRA J0800 Injection, corticotropin, up to 40 units ACTHAR HP J9042 Injection, brentuximab vedotin,
More informationPrior Authorization Drug List
Prior Authorization Drug List Most prescriptions are filled right away when you take them to the pharmacy. But some drugs need to be reviewed by your health plan before they re covered. This process is
More informationPrior Authorization (PA) List for: Fully Insured Plans Effective and Current as of: January 1, 2017 Phone: or
Prior Authorization (PA) List for: Fully Insured Plans Effective and Current as of: January 1, 2017 Phone: 877.449.2884 or 859.335.3737 It is recommended to verify benefits and authorization requirements
More informationSan Francisco Health Service System
San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT
More informationPremium Prior Authorization
Premium Prior Authorization Some medications must be authorized for coverage because they re only approved or effective in treating specific illnesses, they cost more or they may be prescribed for conditions
More informationContinued Development of Approved Biological Drugs
Continued Development of Approved Biological Drugs A Quantitative Study of Additional Indications Approved Postlaunch in the United States White Paper December 2007 Maya Said Charles-André Brouwers Peter
More informationAll of Colorado HealthOP's networks use the Cigna Performance product for our prescription drug coverage.
All of Colorado HealthOP's networks use the Cigna Performance product for our prescription drug coverage. Please see the Cigna Specialty Pharmacy Drug List below for the speciality prescription drug list
More informationFuture strategies for pricing and market access in oncology
Future strategies for pricing and market access in oncology Discussion document October, 2014 BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON Agenda We review
More informationNovel strategies for antibody discovery and optimization
Novel strategies for antibody discovery and optimization Rene Hoet, Biologics, Head of Antibody Lead Discovery rene.hoet@bayer.com, Berlin, February 1, 2016 Agenda Biologics at Bayer Success and Future
More informationCompanies Perspective on Biosimilars
Companies Perspective on Biosimilars Pharma Delegate Healthcare Seminar, 1 st July 2016 American Club, Tokyo, Japan Hideaki Nomura FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. Agenda Why Biosimilars? Current
More informationEvaluatePharma World Preview 2016, Outlook to 2022
EvaluatePharma World Preview 2016, Outlook to 2022 9th Edition September 2016 Welcome to the EvaluatePharma World Preview 2016, Outlook to 2022 The ninth edition of EvaluatePharma s World Preview brings
More information2016 OptumRx Trend Insights
2016 OptumRx Trend Insights TREND SUMMARY Overall trend summary This report offers our perspective of the forces driving trend and spending for 2015 vs. 2016. We define trend as growth in year-over-year
More informationPerspectives Spring The Drug Pipeline: What s in it and why it matters.
Perspectives Spring 2016 The Drug Pipeline: What s in it and why it matters. 2 The Drug Pipeline: What s in it and why it matters. Author: Mark Jackson, BScPhm, BComm, RPh Consultant Pharmacist, TELUS
More informationANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES
ANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES Overview This document provides all new, revised and existing Policies and all new, revised and existing claims editing rules administered
More informationAdventist Health System Employee Health Plan Medical Drug Authorization List. Updated: May 1, 2018
Adventist Health System Employee Health Plan 2018 Medical Drug Authorization List Updated: May 1, 2018 Health First Commercial Plans, Inc. is doing business under the name of Florida Hospital Care Advantage.
More informationREAL WORLD EVIDENCE. Case Studies on Real World Evidence Impacting Payer Decisions
REAL WORLD EVIDENCE 2013 Case Studies on Real World Evidence Impacting Payer Decisions 1 Case Studies on Real World Evidence Impacting Payer Decisions INDEX BY COUNTRY CANADA... 2 FRANCE... 3 GERMANY....
More informationMRC Technology. A Life Science Specialist Technology Transfer Company. Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011
MRC Technology A Life Science Specialist Technology Transfer Company Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011 Dr John Kelly, Associate Director Business Development John.kelly@tech.mrc.ac.uk
More informationResearch Brief. Findings From HSC NO. 22, APRIL Limited Options to Manage Specialty Drug Spending
Research Brief Findings From HSC NO. 22, APRIL 2012 Limited Options to Manage Specialty Drug Spending BY HA T. TU AND DIVYA R. SAMUEL Spending on specialty drugs typically high-cost biologic medications
More informationThe Development of Therapeutic Monoclonal Antibody Products. A Comprehensive Guide to CMC Activities from Clone to Clinic Second Edition
The Development of Therapeutic Monoclonal Antibody Products A Comprehensive Guide to CMC Activities from Clone to Clinic Second Edition Acknowledgements BioProcess Technology Consultants gratefully acknowledge:
More informationUnderstanding Biosimilars and Projecting the Cost Savings to Employers Update
Understanding Biosimilars and Projecting the Cost Savings to Employers Update Prepared by: Milliman, Inc. Frank Kopenski Jr, ASA, MAAA Principal and Consulting Actuary Katie Holcomb, FSA, MAAA Actuary
More informationYour Prescription Drug [ or 20%] Plan with Refill By Mail
Refill By Mail The Home Delivery Pharmacy sends drugs you take on a regular basis right to your door. And you get a larger supply of medicine for less money. 1 Your Prescription Drug [15-40-75 or 20%]
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationCDER New Drug Review: 2014 Update
CDER New Drug Review: 2014 Update John K. Jenkins, M.D. Director, Office of New Drugs Center for Drug Evaluation and Research FDA/CMS Summit December 11, 2014 Slides posted at: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproduct
More informationCENTENE PHARMACY THERAPEUTICS COMMITTEE THIRD QUARTER 2017 CLINICAL POLICY (BIOPHARM) SUMMARY TABLE Coverage Guideline/Policy &
Coverage Guideline/Policy & Status Revision Summary Description Procedure CP.PHAR.14 Hydroxyprogesterone Caproate (Makena/compound) No criteria changes. Added compound to the title. Background section
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > June 2016 New drug information Epclusa (sofosbuvir/velpatasvir): The Food and Drug Administration (FDA) approved Gilead s Epclusa for all forms of hepatitis
More informationSovaldi Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.44 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationUnderstanding the Prescription Drug Landscape & Best Practices for Managing the Benefit
Understanding the Prescription Drug Landscape & Best Practices for Managing the Benefit Diane Clausen Pharmacy Benefit Consultant Pharmaceutical Strategies Group, LLC 5360 Legacy Drive Building 3, Suite
More informationCOMMUNITY OUTREACH STRATEGIES
COMMUNITY OUTREACH STRATEGIES Program Overview & Strategies Table of Contents Program Overview & Strategies... 2,3 Best Practices... 4 Promotional Materials... 5 Sample Promotional Materials... 6,7 Frequently
More informationProcedures, programs and drugs you must precertify
Procedures, programs and drugs you must precertify Participating provider precertification list Starting April 1, 2018 Applies to: Aetna plans, except Traditional Choice plans All health benefits and insurance
More informationSpecialty Drug Spending
Specialty Drug Spending The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible
More informationPharmaceutical Innovation Index 2018
Pharmaceutical Innovation Index 2018 White paper: Celebrating the most innovative companies in pharma The path-to-market design practice Pharmaceutical Innovation Index 2018 Top 10: The PII ranks companies
More informationProcedures and services requiring prior authorization
Procedures and services requiring prior authorization Moda Health Commercial Group and Individual Members Updated 04/10/2018 Services requiring prior authorization Urgent/Emergent Admission Inpatient Elective
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationVan monoklonale antilichamen tot nanolichamen: basisprincipes en technologie
Van monoklonale antilichamen tot nanolichamen: basisprincipes en technologie Prof. Paul Declerck Laboratorium voor Therapeutische en Diagnostische Antilichamen KU LEUVEN Monoklonale antilichamen Wie zijn
More informationRevolutionizing the Treatment of Autoimmune Disorders and Malignancies
Revolutionizing the Treatment of Autoimmune Disorders and Malignancies John Fowler, Co-Founder and CEO Jefferies Healthcare Conference June 7, 2017 Kezar Life Sciences Executive Summary Corporate Background
More informationPERSONALIZED MEDICINE AT FDA Progress Report
PERSONALIZED MEDICINE AT FDA 2017 Progress Report 2 2017 MILESTONES 1. Record number of personalized medicine approvals 2. Approval of first three gene therapies 3. First approval of tissue agnostic indication
More informationPfizer Pipeline. As of October 31, 2017
Pfizer Pipeline As of October 31, 2017 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
More informationAccess Delayed, Access Denied 2012
Studies in HEALTH POLICY April 2012 Access Delayed, Access Denied 2012 Waiting for New Medicines in Canada by Mark Rovere and Brett J. Skinner Key findings On average, Canadians wait over two years for
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationACTELION S COMPANY PROFILE
ACTELION S Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. The company
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationParticipating provider precertification list
Participating provider precertification list Procedures, programs and drugs you must precertify Effective March 1, 2018 For additional information, read all general precertification information. Applies
More informationInjections, Vaccines, and Other Physician- Administered Drugs
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Injections, Vaccines, and Other Physician- Administered Drugs L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 3 4 P U B L I S
More informationStrategic Report. Andy Glowalla, Lead Consultant Elizabeth Davis, Consultant J.R. Hall, Consultant
Strategic Report Andy Glowalla, Lead Consultant Elizabeth Davis, Consultant J.R. Hall, Consultant 19 April 2004 Genentech, Inc. / 2 Background History 3 Products 3 Research & Development 5 Pipeline 5 Manufacturing
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationWHAT S IN A NAME? The Importance of Biosimilar Nonproprietary Names for Healthcare Innovation
POLICY PAPER WHAT S IN A NAME? The Importance of Biosimilar Nonproprietary Names for Healthcare Innovation Sumant Ramachandra, M.D., Ph.D. Senior Vice President and Chief Scientific Officer EXECUTIVE SUMMARY
More informationCMS Reveals Plans to Test Lower ASP Add-On, Value-Based Strategies in Part B
Volume 13, Number 3 March 2016 News and Strategies for Managing High-Cost Specialty Products 3 4 5 6 8 9 10 Contents Trend Toward Separate Medical, Pharmacy Deductibles Grows More Hepatitis C Therapies
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationThe Data and Analytics of the New Life Sciences Marketplace 9 th International Pharmaceutical Compliance Congress and Best Practices Forum
The Data and Analytics of the New Life Sciences Marketplace 9 th International Pharmaceutical Compliance Congress and Best Practices Forum Dr. Frank Wartenberg President Central Europe 13. May 2015 Governments
More informationThe Biotech Millionaire Map
Nicholas Vardy s SPECIAL REPORT For Bull Market Alert Subscribers Only The Biotech Millionaire Map 1 IMPORTANT NOTE: This special report is for information and educational purposes only based on data as
More informationOctober 23+24, Dr. Axel Herberg, CEO
Gerresheimer: Excellent prospects as a unique supplier to the Pharma & Life Science Industry Gerresheimer Capital Markets Day October 23+24, 2008 Dr. Axel Herberg, CEO 0 Disclaimer This presentation may
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B006 Page 1 of 5 and Therapeutics Quality PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationIndustry Surveys Biotechnology
Industry Surveys Biotechnology Steven Silver, Biotechnology Equity Analyst FEBRUARY 2013 Current Environment... 1 Industry Profile... 9 Industry Trends... 9 How the Industry Operates... 19 Key Industry
More informationWebinar Series: Biosimilars
May 23, 2017 Webinar Series: Biosimilars Recent and Upcoming BPCIA Guidance from the Federal Circuit and the Supreme Court John Adkisson Principal Twin Cities Tasha Francis Associate Twin Cities Jenny
More informationDR NEIL FISHER. Helicon Medical Writing Ltd, Director
PROFILE I am an experienced writer, skilled in writing and editing a wide range of medical communications and healthcare education documents for a variety of audiences. Integral to this is my command of
More informationDRUG Naltrexone Implantable Pellets: This document addresses extended-release, implantable naltrexone.
October 1, 2016 [Business Name] [Address] [City], [State] [Zip] Dear Provider: Anthem Blue Cross is pleased to provide you with our updated and new Medical Policies and Clinical UM Guidelines. The updated
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationCommitted to innovation and growth
Committed to innovation and growth Roland Diggelmann, CEO Roche Diagnostics Philadelphia, 02 August 2016 HY 2016 Group results Diagnostics Business model & strategy HY 2016 overview Investing in innovation
More informationNew Drugs Approved in May 2017
New Drugs Approved in May 2017 Review Category Date No. New / Partial Oncology drugs May 18, 2017 1 Xalkori Capsules 200 mg Xalkori Capsules 250 mg (Pfizer Japan Inc.) Crizotinib Drugs with a new additional
More informationReassessing European Biotech Galapagos, Innate top picks
Reassessing European Biotech Galapagos, Innate top picks Equity Research Galapagos and Innate Pharma our top picks in Europe Biotech We revisit our estimates and recommendations across European biotech.
More informationWhat we don t yet know could change everything. Genentech 2002 Annual Report
What we don t yet know could change everything. Genentech 2002 Annual Report The acceleration of scientific knowledge over time has been profound and it is ceaseless. Today, the span of time between great
More informationMEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication
MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may
More informationBiosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective)
Soul, September 14, 2017 Biosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective) Vs17i13 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL HCN Exception/Other PALIVIZUMAB SYNAGIS 18564 Synagis may be covered during the RSV season from October 15, 2017 and March 31, 2018. If the PA is received prior to October 15, 2017,
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationTREATMENT OVERVIEW themmrf.org
MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationMay 26, Re: IVIG Administration Codes, RAC Audits
May 26, 2011 Re: IVIG Administration Codes, RAC Audits Arnold Balanoff, MD Chief Medical Officer Office of the Regional Administrator 601 E. 12th Street, Suite 235 Kansas City, MO 64106 In order to provide
More informationBritish Journal of Clinical Pharmacology
Page 2 of 6 Are there any differences in the regulations of personalised medicine among the US, EU, and Japan? Rumiko Shimazawa, Masayuki Ikeda Graduate School of Biomedical Sciences, Nagasaki University
More informationHigh Cost Drugs Clinical Coding Standards and Guidance OPCS-4
High Cost Drugs Clinical Coding Standards and Guidance OPCS-4 Clinical Classifications Service Date 6 th March 2014 1 Copyright 2014, Health and Social Care Information Centre. Contents Introduction...
More informationFDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now
FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now By Angela Maas, Managing Editor April 2017Volume 14Issue 4 In late March, the FDA went on an approval tear, paving the
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS Preferred Home Delivery Program for Maintenance Medications 1. What are maintenance medications? Maintenance medications are prescription drugs that you need to take regularly.
More informationREFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in Japan The Rheumatoid Arthritis
More informationDenver, Colorado March 3, 2016 NASDAQ: LGND
Deutsche Bank Pharma One on One Day Denver, Colorado March 3, 2016 NASDAQ: LGND Safe Harbor Statement The following presentation contains forward looking statements regarding Ligand s prospects, plans
More informationTransitioning to Express Scripts
Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationPost-Transplant Essential Data
Post-Transplant Essential Data Registry Use Only Sequence Number: Date Received: OMB No: 0915-0310 Expiration date: 01/31/2020 Public Burden Statement: An agency may not conduct or sponsor, and a person
More informationBarriers towards uptake of Biosimilars and how to solve them. Separate facts from fiction.
Barriers towards uptake of Biosimilars and how to solve them. Separate facts from fiction. Prof. Arnold G. Vulto PharmD PhD FCP Hospital Pharmacist / Pharmacologist Professor of Hospital Pharmacy & Practical
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationWINNING BRAND VS. GENERIC COMPETITION
WINNING BRAND VS. GENERIC COMPETITION - Competition 2.0: Brands vs. Generics - Winning Beyond the Molecule www.bernardassociatesllc.com Innovator and generic companies are colliding as they invade each
More informationFDA Approves Teva Version of Neupogen; Uptake May Forecast Biosimilar Acceptance
Volume 9, Number 9 September 2012 News and Strategies for Managing High-Cost Specialty Products 4 5 7 8 9 11 12 Contents Experiences of Genentech, KV May Offer Lessons for Genzyme Allion Sells MOMS Pharmacy;
More informationRoche (ROG VX) EQUITY RESEARCH EUROPE
Switzerland Healthcare Pharmaceuticals Roche (ROG VX) TOGA Party: Opportunity In The Face Of Adversity Key Takeaway New product launches and indications are being underestimated for Roche whilst the fear
More informationPut Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits
Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits Presented by Howard Mazzafro, Vice President Innovative Slide 1 of 25 Solutions. Enduring Principles. Innovative Solutions.
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationOrphan Drugs: Will they be Fostered by Biotech Alone?
Orphan Drugs: Will they be Fostered by Biotech Alone? Nabil Mouline, MBA, Consultant Michael Rice, MS, MBA, Consultant Defined Health s Insight Series Basking Ridge, NJ Basel, Switzerland Berlin, Germany
More informationPalivizumab (Synagis ) Criteria for the Respiratory Syncytial Virus (RSV) Season for Fee-For-Service Legacy Medicaid Recipients
Palivizumab (Synagis ) Criteria for the 2017-2018 Respiratory Syncytial Virus (RSV) Season for Fee-For-Service Legacy Medicaid Recipients Palivizumab is indicated for the prevention of serious lower respiratory
More informationClinigen Group - Peter George (CEO) Right Drug Right Patient Right Time
Clinigen Group - Peter George (CEO) Right Drug Right Patient Right Time Group overview Global specialty pharmaceuticals and services business, supplying clinical trial, licensed and unlicensed critical,
More informationMeridian Health Plan Pharmaceuticals Billed Under the Medical Benefit
0129 Abatacept 0586 AbobotulinumtoxinA 9264 Abraxane (paclitaxel protein bound) 3262 Actemra (tocilizumab) 0800 Acthar Gel 0135 Adalimumab 9287 Adcetris (brentuximab vedotin) 2046 Aflibercept 0180 Agalsidase
More information